Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

This publication has 25 references indexed in Scilit:

• Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I
  Journal of Clinical Investigation, 2001
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001
• Treatment of hyperlipidemia with combined niacin–statin regimens
  The American Journal of Cardiology, 1998
• Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
  Metabolism, 1998
• Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia∗∗See Appendix for list of principal investigators, study sites, and laboratory sites.
  The American Journal of Cardiology, 1998
• Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 Cells
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1997
• Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
  New England Journal of Medicine, 1997
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
  New England Journal of Medicine, 1996
• Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B
  New England Journal of Medicine, 1990
• Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin
  Metabolism, 1985